Glipterin

Glipterin is a prescription medication that contains the active ingredient sitagliptin, a dipeptidyl peptidase‑4 (DPP‑4) inhibitor, supplied in oral tablet form for the European market. It is classified as an antidiabetic drug used to improve glycemic control in adults with type 2 diabetes mellitus. The product does not contain a listed strength in the available data. It is marketed under the brand name Glipterin and requires a physician’s prescription.

Glipterin (sitagliptin) is indicated for the management of type 2 diabetes mellitus as part of a comprehensive treatment plan that includes diet, exercise, and other glucose‑lowering therapies.

- Use as monotherapy in patients who cannot achieve glycemic targets with diet and exercise alone. - Combine with metformin when metformin alone does not provide adequate control. - Add to sulfonylureas, thiazolidinediones, or insulin when additional reduction in HbA1c is needed. - Consider in patients with renal impairment where dose adjustment is recommended according to renal function. - May be used in elderly patients when individualized dosing is applied.

The safety profile of sitagliptin includes a range of adverse events that are generally classified by frequency and severity.

Common: - Upper respiratory tract infection (e.g., nasopharyngitis). - Headache. - Gastrointestinal discomfort such as nausea or abdominal pain. - Mild hypoglycemia when combined with insulin or sulfonylureas.

Serious: - Pancreatitis (severe abdominal pain). - Severe hypersensitivity reactions including angioedema or Stevens‑Johnson syndrome. - Acute renal failure in patients with pre‑existing kidney disease. - Heart failure exacerbation reported in rare cases.

Before initiating Glipterin, clinicians should evaluate several clinical factors to minimize risks and ensure appropriate use.

- Assess renal function; dose may need adjustment in moderate to severe impairment. - Review history of pancreatitis; avoid use if active pancreatitis is present. - Monitor for signs of hypersensitivity, especially skin rash or swelling. - Use caution in patients with a history of heart failure. - Consider pregnancy and lactation status; safety data are limited. - Evaluate concomitant use of strong CYP3A4 or P‑glycoprotein inhibitors.

Sitagliptin can interact with other medicines, affecting its concentration or the effect of co‑administered drugs.

Avoid: - Strong CYP3A4 or CYP2C8 inhibitors (e.g., ketoconazole, gemfibrozil) that may increase sitagliptin exposure. - Concurrent use with insulin secretagogues that may cause severe hypoglycemia without dose adjustment.

Use with caution: - Diuretics and antihypertensives, as fluid shifts may affect renal clearance. - Rifampin or other enzyme inducers that can lower sitagliptin levels. - Other DPP‑4 inhibitors; combined effect is not recommended. - NSAIDs or nephrotoxic agents in patients with reduced kidney function.